Patient & Caregiver Survey
Drug combination regimen nivolumab+ipilimumab (Opdivo+Yervoy)
Kidney Cancer Canada | Cancer du rein Canada is seeking input from kidney cancer patients and their caregivers about their experiences and challenges with kidney cancer and current treatments. The results of this survey will help inform our submission to the pan-Canadian Oncology Drug Review (pCODR) for the drug combination regimen nivolumab+ipilimumab (Opdivo+Yervoy) a new treatment option for patients with previously untreated, advanced or metastatic renal cell carcinoma (RCC). Your input is very important to us.
This survey will take 10 - 15 minutes to complete. We ask that you complete the survey bySaturday May 5 2018 . Please feel free to forward the link to this survey to other kidney cancer patients or caregivers throughout Canada and other countries. The greater the response, the stronger the patient voice will be.
It is important to note that there are new treatments for renal cell carcinoma in the pipeline. This is good news for patients. Kidney Cancer Canada will have another patient and caregiver survey to inform yet another submission to the pan-Canadian Oncology Drug Review (pCODR) in the coming weeks. Stay tuned!
If you have any questions about this survey, please write to us at firstname.lastname@example.org and include Patient and Caregiver Survey in the subject line of the email.